Skip to main content
Premium Trial:

Request an Annual Quote

Marvin Cassman, David Haussler, Janet Thornton, Gregory Sessler


Marvin Cassman has been appointed director of the Institute for Quantitative Biomedical Research (QB3), a new multi-campus effort based at the University of California, San Francisco, with additional facilities planned for UC’s Berkeley and Santa Cruz campuses.

Cassman is currently director of the National Institute of General Medical Sciences of the NIH. As director of the QB3 Institute, Cassman will “oversee innovative programs designed to integrate physical, mathematical, and engineering sciences to create powerful new techniques for attacking biological problems,” according to a QB3 statement.

The institute will be organized around three research and education modules: bioengineering and biotechnology, bioinformatics, and structural and chemical biology. It will focus on “developing techniques for storing and analyzing vast quantities of biological information and using imaging and mathematical modeling to view molecules, cells, and single organ systems as part of functional networks.”

David Haussler will direct QB3 efforts at the UC Santa Cruz campus.


Janet Thornton, director of the European Bioinformatics Institute, was honored last week for her work in protein structure modeling and analysis. Giving the Feodor Lynen Lecture at the Nature Biotechnology Winter Symposium in Miami, Fla., Thornton spoke about the need to identify the “druggable proteome.”

Among numerous other honors, Thornton was made a Commander of the British Empire last year.


Seattle-based Icogen has appointed Gregory Sessler, former senior vice president and chief financial officer of Rosetta Inpharmatics, to its board of directors.

Filed under

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.